- Home
- LX vs BEAM Comparison
LX vs BEAM Comparison
Compare LX & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LX
- BEAM
- Stock Information
- Founded
- LX 2013
- BEAM 2017
- Country
- LX China
- BEAM United States
- Employees
- LX N/A
- BEAM N/A
- Industry
- LX Finance: Consumer Services
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LX Finance
- BEAM Health Care
- Exchange
- LX Nasdaq
- BEAM Nasdaq
- Market Cap
- LX 1.7B
- BEAM 1.8B
- IPO Year
- LX 2017
- BEAM 2020
- Fundamental
- Price
- LX $6.99
- BEAM $17.00
- Analyst Decision
- LX
- BEAM Strong Buy
- Analyst Count
- LX 0
- BEAM 11
- Target Price
- LX N/A
- BEAM $50.50
- AVG Volume (30 Days)
- LX 5.1M
- BEAM 3.0M
- Earning Date
- LX 05-22-2025
- BEAM 05-06-2025
- Dividend Yield
- LX 2.60%
- BEAM N/A
- EPS Growth
- LX 2.29
- BEAM N/A
- EPS
- LX 0.89
- BEAM N/A
- Revenue
- LX $1,945,937,716.00
- BEAM $63,518,000.00
- Revenue This Year
- LX $9.24
- BEAM N/A
- Revenue Next Year
- LX $6.03
- BEAM $6.32
- P/E Ratio
- LX $7.87
- BEAM N/A
- Revenue Growth
- LX 8.78
- BEAM N/A
- 52 Week Low
- LX $1.56
- BEAM $13.53
- 52 Week High
- LX $11.64
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- LX 36.05
- BEAM 40.71
- Support Level
- LX $6.77
- BEAM $16.04
- Resistance Level
- LX $7.50
- BEAM $17.94
- Average True Range (ATR)
- LX 0.67
- BEAM 1.84
- MACD
- LX -0.25
- BEAM 0.26
- Stochastic Oscillator
- LX 16.46
- BEAM 44.24
About LX LexinFintech Holdings Ltd.
LexinFintech Holdings Ltd is an online consumer finance platform and a technology-driven service provider in China. The group is engaged in online direct sales services and online consumer finance services for its customers in the PRC. Geographically, it derives revenue from China.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.